510(k) device
HydroPearl Microspheres
MicroVention, Inc. · Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia (NOY, Class II) · First FDA decision Jan 22, 2020, newest Jan 22, 2020Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
4
Naming "HydroPearl Microspheres"
MAUDE reports
0
Brand "HydroPearl Microspheres", since 2015
PubMed studies
3
Mentioning "HydroPearl Microspheres"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HydroPearl Microspheres
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HydroPearl Microspheres510(k)
K192684 · Decided Jan 22, 2020 · 118 days after receipt
Device type: Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia (NOY) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)Local determinationIn effectL38378CGS Administrators, LLCUpdated Mar 25, 2026
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "HydroPearl Microspheres", any status and sponsor, newest update first.
- An Observational Study of Radial Access Embolization Procedures Using HydroPearl MicrospheresCompleted
Terumo Medical CorporationPublic (4543.T)
NCT04272216 · 99 participants · Start Feb 6, 2020 · Primary completion Mar 7, 2022
Device: Treatment with HydroPearl via radial access · For: Uterine Fibroid; Arteriovenous Malformations; Hypervascular Tumors and 1 more
Sites: Los Angeles, California; Chicago, Illinois; St Louis, Missouri · 6 sites in all
Andrew PicelAcademic, hospital or other
NCT04472091 · 0 participants · Start Jan 15, 2025 · Primary completion Nov 1, 2026
Device: Genicular artery embolization (GAE) · For: Knee Osteoarthritis; Knee Pain Chronic; Knee Pain Swelling and 2 more
Sites: Palo Alto, California
University of ChicagoAcademic, hospital or other
NCT04592562 · 5 participants · Start Sep 22, 2021 · Primary completion May 28, 2024
Device: the Terumo Hydropearl® microspheres device · For: Knee Osteoarthritis
Sites: Chicago, Illinois
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HydroPearl Microspheres", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NOY
3 reports: 0 malfunction, 2 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0868-2024 · Started Dec 21, 2023 · Posted by FDA Jan 31, 2024
Reason given: Due to, during the manufacturing process, the prescribed manufacturing and quality processes were not followed and the product was inadvertently distributed.
Cause as FDA categorized it: Device Design · Device type: Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia (NOY)
Published research
The most relevant PubMed records for "HydroPearl Microspheres"[tiab]. The summary above synthesizes these.
- Polyethylene Glycol microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids.
Nardelli F, Ciferri F, Muratore P, et al. · Radiol Med · 2025
- Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids.
Patetta MA, Isaacson AJ, Stewart JK · CVIR Endovasc · 2021
- The RAVI registry: prospective, multicenter study of radial access in embolization procedures - 30ߙdays follow up.
Guimaraes M, Fischman A, Yu H, et al. · CVIR Endovasc · 2024
Other devices of this type
Also filed under product code NOY.
- Bead Block (100 - 300µmBiocompatibles UK Ltd (Part of Boston Scientific Corporation · 510(k) 2021
- Embozene Color-Advanced MicrospheresBoston Scientific · 510(k) 2018
- Embosphere MicrospheresBiosphere Medical, S.A. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.